AMSTERDAM / LONDON (IT BOLTWISE) – Polpharma Group, a major player in the Central and Eastern European pharmaceutical industry, has announced a change in leadership. Markus Sieger will step down as CEO after ten years and Sebastian Szymanek will take over as CEO from January 2026. This change marks a strategic step in the company’s further development.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
Polpharma Group, one of the largest pharmaceutical companies in Central and Eastern Europe and Central Asia, has announced a significant leadership change. From January 1, 2026, Sebastian Szymanek will take on the role of CEO, while Markus Sieger will step down as CEO after a successful decade. However, Sieger will continue to support the group’s strategic development as a member of the Supervisory Board.
Under the leadership of Markus Sieger, the Polpharma Group has achieved remarkable success. The company was not only able to grow financially, but also successfully implement its mission of helping people lead healthy lives. Polpharma has established itself as a reliable partner for healthcare systems in Europe and Central Asia, providing high-quality, affordable medicines to millions of patients.
The owner of Polpharma Group, Jerzy Starak, praised Markus Sieger for his outstanding commitment and visionary ideas, which have significantly contributed to positioning the company in a dynamic market environment. Starak emphasized that Sieger has strengthened the company’s values and set a strategic course for the future. The appointment of Sebastian Szymanek as the new CEO is seen as a continuation of this strategic direction.
Sebastian Szymanek brings almost 30 years of experience in the pharmaceutical industry and has held several key leadership positions since joining Polpharma in 2007. His extensive knowledge of both the generics and innovation industries make him the ideal choice for the role of CEO. Under his leadership, Polpharma is expected to further strengthen its market position and advance innovative projects.
Nick Haggar, Chairman of the Polpharma Group Supervisory Board, expressed confidence that Szymanek has the right qualifications to lead the company into the next phase of growth. Thanks to his in-depth knowledge of the company and his proven leadership qualities, he will continue to drive the group’s innovative strength.
*Order an Amazon credit card with no annual fee with a credit limit of 2,000 euros! a‿z
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ «KI Gadgets»
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Polpharma Group announces leadership change: Sebastian Szymanek becomes new CEO”.
The post Sebastian Szymanek wird neuer CEO appeared first on Veritas News.
